

Financial news for CANF dated on 2020-06-11: 80 Biggest Movers From Yesterday

Financial news for CANF dated on 2020-06-10: 61 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CANF dated on 2020-06-10: Can-Fite BioPharma Reports 3.902M ADS For \$2.05/ADS

Financial news for CANF dated on 2020-06-09: Following Pre-IND Guidance From FDA Can-Fite To Advance Piclidenoson Into Phase II COVID-19 Trial In The US

Financial news for CANF dated on 2020-06-08: Can-Fite Participating in BIO Digital International Convention And One-on-One Partnering Meetings On June 8-12, 2020

Financial news for CANF dated on 2020-06-04: Can Fite Says Following Meetings With FDA And EMA, Co To Submit Protocol, Conduct 1 Pivotal Trial For Registration In Both Markets For Namodenoson

Financial news for CANF dated on 2020-06-01: Can Fite Biofarma shares are trading lower after the company reported worse-than-expected Q1 sales results.

Financial news for CANF dated on 2020-06-01: Can-Fite Biopharma Q1 EPS \$(0.03) Beats \$(0.66) Estimate, Sales \$198.00K Miss \$1.18M Estimate

Financial news for CANF dated on 2020-05-27: 96 Biggest Movers From Yesterday

Financial news for CANF dated on 2020-05-26: 61 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CANF dated on 2020-05-26: 28 Stocks Moving in Tuesday's Pre-Market Session

Financial news for CANF dated on 2020-05-26: 71 Biggest Movers From Friday

Financial news for CANF dated on 2020-05-21: Can Fite Biofarma shares are trading higher after the company received a notice of allowance for Namodenoson patent in treatment of NASH and NAFLD.

Financial news for CANF dated on 2020-05-21: Can-Fite Reports Receives Notice Of Allowance For Namodenoson Patent In Treatment Of NASH, NAFLD From US PTO

Financial news for CANF dated on 2020-05-15: Can-Fite BioPharma Reports Pre-Investigational New Drug Application Submission To FDA For Piclidenoson In Treatment Of Coronavirus-Infected Patients With Moderate-To-Severe Symptoms

Financial news for CANF dated on 2020-04-20: 95 Biggest Movers From Friday

Financial news for CANF dated on 2020-04-17: 58 Stocks Moving In Friday's Mid-Day Session

Financial news for CANF dated on 2020-04-17: 70 Biggest Movers From Yesterday

Financial news for CANF dated on 2020-04-16: 52 Stocks Moving In Thursday's Mid-Day Session

Financial news for CANF dated on 2020-04-16: 52 Stocks Moving In Thursday's Mid-Day Session

Financial news for CANF dated on 2020-04-16: 33 Stocks Moving in Thursday's Pre-Market Session

Financial news for CANF dated on 2020-04-14: 86 Biggest Movers From Yesterday

Financial news for CANF dated on 2020-04-13: Mid-Afternoon Market Update: Crude Oil Up 2%; Biocept Shares Surge

Financial news for CANF dated on 2020-04-13: 63 Stocks Moving In Monday's Mid-Day Session

Financial news for CANF dated on 2020-04-13: Mid-Day Market Update: Dow Falls Over 500 Points; SCWorx Shares Spike Higher

Financial news for CANF dated on 2020-04-13: Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics

Financial news for CANF dated on 2020-04-13: Can Fite Biofarma shares are trading higher after the company announced it has received approval to initiate a pilot clinical study of its drug candidate, Piclidenoson, for the treatment of moderate-to-severe symptoms in coronavirus infected patients.

Financial news for CANF dated on 2020-04-13: 30 Stocks Moving in Monday's Pre-Market Session

Financial news for CANF dated on 2020-04-13: Can-Fite BioPharma Receives Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately

Financial news for CANF dated on 2020-04-07: Why Can-Fite's Stock Is Moving Higher Today

Financial news for CANF dated on 2020-04-07: Can Fite Biofarma shares are trading higher after the company announced it significantly achieved its main study endpoint in phase 2 NASH Study with Namodenoson were dose-dependent. UPDATE: Shares have since reversed, now lower.

Financial news for CANF dated on 2020-04-07: Can-Fite Reports Main Study Endpoints In Phase 2 NASH Study With Namodenoson Were Dose Dependent, Significantly Achieved

Financial news for CANF dated on 2020-04-03: CanFite Shares Spike To Session High, Up 19%; Traders Circulate Apr. 3-Dated ClinicalTrials.gov Study Record Detail For Piclidenoson For Coronavirus Infection

Financial news for CANF dated on 2020-03-30: Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020

Financial news for CANF dated on 2020-03-28: The Week In Cannabis: Marijuana Stocks Outperform S&P Again As Weed Is Deemed 'Essential' In COVID-19 Times

Financial news for CANF dated on 2020-03-27: Can-Fite Posts \$9.6M Net Loss, Provides Clinical Trials Updates

Financial news for CANF dated on 2020-03-27: Can-Fite Biopharma FY19 Net Loss \$9.5M vs \$6.6M In FY18, Sales \$2M vs \$3.8M In FY18

Financial news for CANF dated on 2020-03-23: Can-Fite Submits its Piclidenoson for Compassionate Use Treatment for Coronavirus Patients in Israel

Financial news for CANF dated on 2020-03-18: Can-Fite to Participate In Digital Bio-Europe Spring Partnering Conference; Says Looks To Partner On Co-Development Of Piclidenoson For Coronavirus Treatment

Financial news for CANF dated on 2020-03-14: The Week In Cannabis: Coronavirus Drop, Major Financing Agreements, Psychedelics Getting Hot

Financial news for CANF dated on 2020-03-13: The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals

Financial news for CANF dated on 2020-03-13: Benzinga Pro's Top 5 Stocks To Watch For Fri., Mar. 13, 2020: GLD, OPK, IBIO, CPB, CANF

Financial news for CANF dated on 2020-03-13: 30 Stocks Moving in Friday's Pre-Market Session

Financial news for CANF dated on 2020-03-13: Can-Fite Reports Will Explore Anti-Coronavirus Effects Of Piclidenoson In Collaboration With Lewis Katz School Of Medicine

Financial news for CANF dated on 2020-03-11: Can-Fite Says Preclinical Study Shows That Small Amounts Of CBD Can Help With Obesity

Financial news for CANF dated on 2020-03-11: Can-Fite Highlights Pre-Clinical Data Demonstrating 'Inhibition of Fat Cell Expansion by Cannabis Derived CBD'

Financial news for CANF dated on 2020-03-06: 101 Biggest Movers From Yesterday

Financial news for CANF dated on 2020-03-05: Mid-Afternoon Market Update: Dow Tumbles Over 900 Points; Comtech Telecommunications Shares Plummet

Financial news for CANF dated on 2020-03-05: 70 Stocks Moving In Thursday's Mid-Day Session

Financial news for CANF dated on 2020-03-05: Mid-Day Market Update: WideOpenWest Falls After Q4 Results; Co-Diagnostics Shares Surge

Financial news for CANF dated on 2020-03-05: Benzinga Pro's Top 5 Stocks To Watch For Thurs., Mar. 5, 2020: ZM, MRVL, LUV, CODX, CANF

Financial news for CANF dated on 2020-03-05: The Daily Biotech Pulse: Trevana Pain

Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19

Financial news for CANF dated on 2020-03-05: Can-Fite Highlights Has US Patent Protecting Anti-Viral Effects Of 2 Drug Candidates, Is Exploring Collaboration To Test Candidates Against Coronavirus

Financial news for CANF dated on 2020-03-05: Can-Fite Sees Data From Interim Analysis Of Piclidenosen In Phase III Trial Expected Q4'20

Financial news for CANF dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for CANF dated on 2020-02-27: Can-Fite, Univo Say Preclinical Data Results Show CBD's Anti-Cancer Effect In Human Liver Cells

Financial news for CANF dated on 2020-02-27: Pre-clinical Studies Demonstrate CBD's Robust Anti-Cancer Effect Against Liver Cancer; Can-Fite and Univo Pharmaceuticals Expand Collaboration Agreement

Financial news for CANF dated on 2020-02-24: Can Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications

Financial news for CANF dated on 2020-02-18: Can-Fite Granted Patent Allowance For Its NASH Drug Namodenoson In South Korea; Co. Notes Results Of Its NASH Phase II Study Are Expected This Quarter

Financial news for CANF dated on 2020-02-11: 80 Biggest Movers From Yesterday

Financial news for CANF dated on 2020-02-10: Can-Fite BioPharma Prices ~3.33M Unit Offering At \$1.50/Unit

Financial news for CANF dated on 2020-02-10: UPDATE: CanFite Shares Halted With Code News Pending

Financial news for CANF dated on 2020-02-10: CanFite Shares Halted

Financial news for CANF dated on 2020-02-03: Can-Fite Completes 50% Patient Enrollment In Phase III Rheumatoid Arthritis Study & Implements Interim Analysis

Financial news for CANF dated on 2020-01-28: 71 Biggest Movers From Yesterday

Financial news for CANF dated on 2020-01-27: Mid-Afternoon Market Update: Crude Oil Down 2%; NeuroMetrix Shares Plummet

Financial news for CANF dated on 2020-01-27: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for CANF dated on 2020-01-21: 30 Stocks Moving in Tuesday's Pre-Market Session

Financial news for CANF dated on 2020-01-16: Can-Fite, Univo Pharma Report Collaboration For Discovery, Applied Patent For Cannabinoid Formulations With Broad Therapeutic Effects

Financial news for CANF dated on 2020-01-10: 64 Biggest Movers From Yesterday

Financial news for CANF dated on 2020-01-09: Mid-Afternoon Market Update: Bed Bath & Beyond Tumbles Following Q3 Miss; Applied Genetic Technologies Shares Jump

Financial news for CANF dated on 2020-01-09: Mid-Day Market Update: Dow Surges Over 200 Points; Tufin Software Technologies Shares Plunge

Financial news for CANF dated on 2020-01-09: 32 Stocks Moving In Thursday's Mid-Day Session

Financial news for CANF dated on 2020-01-09: Can-Fite Announces Exercise Of Warrants For Cash Proceeds Of \$2.4M

Financial news for CANF dated on 2020-01-06: Can-Fite BioPharma Expects Topline Results from its NASH Phase 2 Study in Q1

Financial news for CANF dated on 2020-01-06: 53 Biggest Movers From Friday

Financial news for CANF dated on 2020-01-03: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for CANF dated on 2020-01-03: Can-Fite Reports Pre-Clinical Data Generated At Hadassah Medical Center Showing Namodenoson Induces Weight Loss In Experimental Models, Normalizes Glucose Levels

Financial news for CANF dated on 2019-12-31: 55 Biggest Movers From Yesterday

Financial news for CANF dated on 2019-12-30: CEO Of Univo Pharmaceuticals Appointed Board Member At Can-Fite

Financial news for CANF dated on 2019-12-30: 58 Biggest Movers From Friday

Financial news for CANF dated on 2019-12-27: 46 Stocks Moving In Friday's Mid-Day Session

Financial news for CANF dated on 2019-12-27: 60 Biggest Movers From Yesterday

Financial news for CANF dated on 2019-12-26: Mid-Afternoon Market Update: Nasdaq Hits 9,000; Spring Bank Pharmaceuticals Shares Slide

Financial news for CANF dated on 2019-12-26: 34 Stocks Moving In Thursday's Mid-Day Session

Financial news for CANF dated on 2019-12-26: Mid-Day Market Update: Crude Oil Up 1%; Spectrum Pharmaceuticals Shares Plunge

Financial news for CANF dated on 2019-12-26: Can-Fite Reports Strategic Partnership With Univo To Develop Cannabinoid-Based Products Is Ongoing

Financial news for CANF dated on 2019-12-09: Can-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial

Financial news for CANF dated on 2019-12-06: 75 Biggest Movers From Yesterday

Financial news for CANF dated on 2019-12-05: 50 Stocks Moving In Thursday's Mid-Day Session

Financial news for CANF dated on 2019-12-05: 72 Biggest Movers From Yesterday

Financial news for CANF dated on 2019-12-04: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CANF dated on 2019-12-03: 75 Biggest Movers From Yesterday

Financial news for CANF dated on 2019-12-02: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for CANF dated on 2019-12-02: 18 Stocks Moving in Monday's Pre-Market Session

Financial news for CANF dated on 2019-12-02: 52 Biggest Movers From Friday

Financial news for CANF dated on 2019-12-01: The Week In Cannabis: FDA Sends Warning Letter, DEA Issues Plan For Cultivation, Kevin Durant Joins Board

Financial news for CANF dated on 2019-11-29: Mid-Day Market Update: Crude Oil Down 4%; SORL Auto Parts Shares Spike Higher

Financial news for CANF dated on 2019-11-29: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for CANF dated on 2019-11-29: Mid-Morning Market Update: Markets Open Lower; Tech Data Shares Climb After \$6B Takeover Bid From Apollo

Financial news for CANF dated on 2019-11-29: Benzinga Pro's Top 3 Stocks To Watch For Fri., Nov. 29, 2019: CANF, PCG, BBY

Financial news for CANF dated on 2019-11-29: Can Fite Biofarma shares are trading higher following Q3 clinical update, highlighting an agreement with the FDA on its liver cancer study design, a South Korean distribution deal and an agreement to develop cannabinoid-based pharmaceuticals and assays.

Financial news for CANF dated on 2019-11-29: 24 Stocks Moving in Friday's Pre-Market Session

Financial news for CANF dated on 2019-11-29: Can-Fite Announces Reached Agreement With FDA On Phase III Liver Cancer Study Design During Q3

Financial news for CANF dated on 2019-11-19: Shares of cannabis companies are trading higher, rebounding from recent weakness following large sell offs. NOTE: The sector has been heavily volatile in recent weeks.

Financial news for CANF dated on 2019-11-19: Can Fite Biofarma Granted Patents In

Canada, South Korea And Israel For Its Sexual Dysfunction Drug

Financial news for CANF dated on 2019-11-18: Shares of several cannabis companies are trading lower in sympathy with Aurora Cannabis after the company announced last week that it would cancel/delay plans for multiple facility expansions and converted some debt into shares in order to conserve cash.

Financial news for CANF dated on 2019-11-15: The Week In Cannabis: Stocks Fall On Poor Earnings, More Americans Support Legalization

Financial news for CANF dated on 2019-11-11: Can-Fite Obtains Patent For Treatment Of Osteoarthritis In Mammals

Financial news for CANF dated on 2019-11-11: 20 Stocks Moving in Monday's Pre-Market Session

Financial news for CANF dated on 2019-11-11: Can-Fite Granted US Patent for Piclidenoson in the Treatment of Osteoarthritis

Financial news for CANF dated on 2019-11-04: 21 Stocks Moving In Monday's Pre-Market Session

Financial news for CANF dated on 2019-11-04: Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients

Financial news for CANF dated on 2019-11-01: 26 Stocks Moving in Friday's Pre-Market Session

Financial news for CANF dated on 2019-11-01: 23 Biggest Movers From Yesterday

Financial news for CANF dated on 2019-10-31: Mid-Afternoon Market Update: US Markets Down, Dow Loses More Than 200 Points

Financial news for CANF dated on 2019-10-31: 27 Stocks Moving In Thursday's Mid-Day Session

Financial news for CANF dated on 2019-10-31: Mid-Day Market Update: Markets Dip After Morning Rise; Oil Plunges

Financial news for CANF dated on 2019-10-31: Mid-Morning Market Update: Markets Inch Up; Bristol-Myers Squibb Reports Q3 Beat

Financial news for CANF dated on 2019-10-31: Can-Fite Shares Rise 45% Premarket on Announcement FDA Agreed with Co's Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer

Financial news for CANF dated on 2019-10-22: 38 Biggest Movers From Yesterday

Financial news for CANF dated on 2019-10-21: 33 Stocks Moving In Monday's Mid-Day Session

Financial news for CANF dated on 2019-10-21: 26 Stocks Moving in Monday's Pre-Market Session

Financial news for CANF dated on 2019-10-18: 38 Stocks Moving In Friday's Mid-Day Session

Financial news for CANF dated on 2019-10-18: 48 Biggest Movers From Yesterday

Financial news for CANF dated on 2019-10-17: 32 Stocks Moving In Thursday's Mid-Day Session

Financial news for CANF dated on 2019-10-15: 25 Stocks Moving in Tuesday's Pre-Market Session

Financial news for CANF dated on 2019-10-15: Can-Fite Completes Patient Enrollment In Phase II NASH Study Of Namodenoson

Financial news for CANF dated on 2019-10-10: Can Fite Highlights Publication Of Namodenoson NASH Mechanism Of Action In International Journal of Molecular Medicine

Financial news for CANF dated on 2019-10-02: 23 Stocks Moving in Wednesday's Pre-Market Session

Financial news for CANF dated on 2019-09-24: H.C. Wainwright Maintains Buy on Can Fite Biofarma, Lowers Price Target to \$3

Financial news for CANF dated on 2019-09-13: The Week In Cannabis: Big Pharma Makes

Moves, Diddy & Wahlberg Go After CBD, Medicine Man Continues M&A Spree

Financial news for CANF dated on 2019-09-12: 71 Biggest Movers From Yesterday

Financial news for CANF dated on 2019-09-11: UPDATE: Capital Point Filing On Can-Fite Shows Firm Filed Request For Temporary Injunction With Tel Aviv-Yafo District Court To Prevent Execution Of Collaboration Deal Between Co. Univo Pharma

Financial news for CANF dated on 2019-09-11: Can-Fite BioPharma Amended 13D Filing From Capital Point Shows 12.88% Stake, Includes Language Firm Initiated Added Legal Proceedings In Tel Aviv-Yafo District Court To Compel Co. To Convene Special General Meeting Of Shareholders

Financial news for CANF dated on 2019-09-11: 48 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CANF dated on 2019-09-11: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday., September 11, 2019

Financial news for CANF dated on 2019-09-11: 26 Stocks Moving in Wednesday's Pre-Market Session

Financial news for CANF dated on 2019-09-11: 80 Biggest Movers From Yesterday

Financial news for CANF dated on 2019-09-10: 50 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CANF dated on 2019-09-10: Can-Fite Partners, Univo Pharmaceuticals Join Forces On Medical Cannabis-Based Therapeutics

Financial news for CANF dated on 2019-09-10: Mid-Morning Market Update: Markets Open Lower; HD Supply Posts Mixed Q2 Results

Financial news for CANF dated on 2019-09-10: 28 Stocks Moving in Tuesday's Pre-Market Session

Financial news for CANF dated on 2019-09-10: Can-Fite shares are trading higher after the company entered into an agreement with Univo Pharmaceuticals to develop cannabinoid-based pharmaceuticals and assays.

Financial news for CANF dated on 2019-09-10: Can-Fite Enters Into Agreement With Univo Pharmaceuticals To Develop Cannabinoid-Based Pharmaceuticals And Assays

Financial news for CANF dated on 2019-09-10: Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays

Financial news for CANF dated on 2019-08-29: Can-Fite Reports Top-Line Data From Phase II Nash Study With Namodenoson Expected Q4 2019

Financial news for CANF dated on 2019-08-29: Can-Fite Reports Preparatory Work For An End Of Phase II Meeting With FDA To Initiate Phase III Study In Liver Cancer Is Ongoing; Patient Enrollment Continues In Two Phase III Studies For Piclidenoson In The Treatment Of Rheumatoid Arthritis And Psoriasis

Financial news for CANF dated on 2019-08-24: 10 Biopharmaceutical Companies Trying To Cure Cancer

Financial news for CANF dated on 2019-08-22: The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study

Financial news for CANF dated on 2019-08-08: The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Financial news for CANF dated on 2019-08-06: Can Fite Biofarma shares are trading higher after the company announced that a supply of Namodenoson has been manufactured and is ready for use in the treatment of advanced liver cancer patients.

Financial news for CANF dated on 2019-08-06: Can-Fite BioPharma Announces That A Supply Of Namodenoson Has Been Manufactured And Is Ready For Use In The Treatment Of Advanced Liver Cancer Patients

Financial news for CANF dated on 2019-08-05: Can-Fite BioPharma 6-K Shows Co. Received Letter From Capital Point On Aug. 1, 2019 Requesting Co. Convene Shareholders Meeting To Amend Articles Of Association, Replace Board Members, Dismiss CEO

Financial news for CANF dated on 2019-08-01: Can-Fite BioPharma Reports \$4M Deal With Kyongbo Pharm

Financial news for CANF dated on 2019-08-01: Can-Fite BioPharma Reports Deal With Kyongbo Pharm For Distribution In South Korea Of Piclidenoson For Psoriasis, Will Receive \$4M Upfront, Milestone Payments

Financial news for CANF dated on 2019-07-10: Can-Fite BioPharma Appeals Lawsuit Against Venture Capital Firm

Financial news for CANF dated on 2019-07-09: UPDATE: Can-Fite Says Supreme Court Granted Motion On Temporary Basis Pending Any Other Decision, Co. Says Will Vigorously Defend Itself

Financial news for CANF dated on 2019-07-09: UPDATE: Can-Fite Says Supreme Court Appeal Filed Motion To Stay Execution Of District Court Pending Decision On Appeal

Financial news for CANF dated on 2019-07-09: Can-Fite BioPharma 6-K Shows Co. Filed Appeal With Supreme Court Appealing Decision Related To Convening Of Special Shareholders Meeting To Replace Directors

Financial news for CANF dated on 2019-06-27: 36 Stocks Moving In Thursday's Pre-Market Session

Financial news for CANF dated on 2019-06-25: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CANF dated on 2019-06-18: Can-Fite BioPharma Files Lawsuit AGAINST Capital Point Alleging 'improper conduct in its attempt to exert control over the Company by, among things, unlawfully requesting that the Company convene a shareholders' meeting to replace its directors.'

Financial news for CANF dated on 2019-06-06: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for CANF dated on 2019-06-03: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for CANF dated on 2019-06-03: Can-Fite's Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session

Financial news for CANF dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for CANF dated on 2019-05-31: 56 Biggest Movers From Yesterday

Financial news for CANF dated on 2019-05-30: The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug

Financial news for CANF dated on 2019-05-29: Can-Fite Biopharma Q1 EPS \$(0.04) Misses \$(0.01) Estimate, Sales \$299K Down From \$632K YoY

Financial news for CANF dated on 2019-05-24: Secondary Offerings Put A Pause On May's Momentum

Financial news for CANF dated on 2019-05-24: Can-Fite Biopharma 8-K Shows Co. Received Letter On Behalf Of Capital Point Stating Firm Acquired Shares Of Co. Representing 5+% Of Outstanding Shares

Financial news for CANF dated on 2019-05-23: 55 Biggest Movers From Yesterday

Financial news for CANF dated on 2019-05-22: Can-Fite 13G Filing From Sabby Mgmt. Shows New 9.79% Stake

Financial news for CANF dated on 2019-05-22: 41 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CANF dated on 2019-05-21: A Look At Benzinga Pro's 10 Most-Searched Tickers For May 21, 2019

Financial news for CANF dated on 2019-05-21: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tue., May 21, 2019

Financial news for CANF dated on 2019-05-21: 52 Biggest Movers From Yesterday

Financial news for CANF dated on 2019-05-20: A Look At Benzinga Pro's 10 Most-Searched Tickers For May 20, 2019

Financial news for CANF dated on 2019-05-20: Can-Fite Shares Resume Trade, Continue Lower; Down 35% For Session

Financial news for CANF dated on 2019-05-20: Can-Fite Shares Resume Trade, Halted On Second Circuit Breaker; Shares Down 30% For Session

Financial news for CANF dated on 2019-05-20: Mid-Afternoon Market Update: Dow Falls Over 100 Points; Sprint Shares Spike Higher

Financial news for CANF dated on 2019-05-20: Can-Fite Shares Resume Trade, Move Lower, Halted On Circuit Breaker, Up 13.6% For Session

Financial news for CANF dated on 2019-05-20: Can-Fite Reports \$6M Registered Direct Offering

Financial news for CANF dated on 2019-05-20: Can-Fite Shares Halted News Pending

Financial news for CANF dated on 2019-05-20: 36 Stocks Moving In Monday's Mid-Day Session

Financial news for CANF dated on 2019-05-20: Mid-Day Market Update: Pinduoduo Falls After Q1 Results; Biocept Shares Jump

Financial news for CANF dated on 2019-05-20: Can-Fite Abstract Selected For Liver Conference

Financial news for CANF dated on 2019-05-20: Mid-Morning Market Update: Markets Open Lower; International Game Technology Earnings Miss Views

Financial news for CANF dated on 2019-05-20: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Mon., May 20, 2019

Financial news for CANF dated on 2019-05-20: Can-Fite Biopharma shares are trading lower after the company announced a \$6 million registered direct offering.

Financial news for CANF dated on 2019-05-20: Can-Fite Reports Its Phase II Liver Cancer Data Selected For Presentation At International Liver Cancer Association

Financial news for CANF dated on 2019-05-06: Can-Fite BioPharma Highlights Is Conducting Preparatory Work For Planned Pivotal Phase III Study Of Namodenoson In Treatment Of Advanced Live Cancer

Financial news for CANF dated on 2019-04-15: Can-Fite Biopharma Recieves a \$1M Payment From CKD for Distribution of Namodenoson in South Korea

Financial news for CANF dated on 2019-04-12: Can-Fite BioPharma 13G From Intracoastal Capital Shows New 9.99% Stake

Financial news for CANF dated on 2019-04-02: Can-Fite BioPharma shares are trading lower after the company reported a \$3.2 million registered direct offering.

Financial news for CANF dated on 2019-04-02: Can-Fite BioPharma Reports \$3.2M Registered Direct Offering

Financial news for CANF dated on 2019-03-27: 58 Biggest Movers From Yesterday

Financial news for CANF dated on 2019-03-26: Mid-Afternoon Market Update: Ameri Holdings Drops After FY18 Results; Bed Bath & Beyond Shares Jump

Financial news for CANF dated on 2019-03-26: 42 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CANF dated on 2019-03-26: Mid-Day Market Update: Crude Oil Up Over 2%; Aldeyra Therapeutics Shares Spike Higher

Financial news for CANF dated on 2019-03-26: Mid-Morning Market Update: Markets Open Higher; Carnival Issues Weak Profit Outlook

Financial news for CANF dated on 2019-03-26: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CANF dated on 2019-03-26: Can-Fite shares are trading lower after the company's phase 2 trial for advanced liver cancer did not meet its primary endpoint.

Financial news for CANF dated on 2019-03-26: Can-Fite Reports Results For Phase II Advanced Liver Cancer Trial , Namodenoson: Did Not Met Primary Endpoint

Financial news for CANF dated on 2019-03-12: Can-Fite BioPharma Filing Shows Registration For ~2.35M ADS Offering Via Selling Shareholders

Financial news for CANF dated on 2019-02-25: Can-Fite Expands its Namodenoson

Distribution Deal with CKD in South Korea with NASH Indication, Can-Fite to Receive \$1M Upfront

Financial news for CANF dated on 2019-02-04: Can-Fite Granted a Patent by the USPTO For its A3 Adenosine Receptor in the Treatment of Osteoarthritis

Financial news for CANF dated on 2019-01-30: Can-Fite Issues Press Release Highlighting 'drugs robustly inhibit the release of inflammatory mediators that induce Cytokine Release Syndrome'

Financial news for CANF dated on 2019-01-24: Can-Fite BioPharma's CEO Issues a Letter to Shareholders

Financial news for CANF dated on 2019-01-24: Can-Fite CEO Sends Letter To Shareholders, Highlights Near-Term Milestones

Financial news for CANF dated on 2019-01-18: Can-Fite BioPharma Announces a 2.24M share registered direct offering at \$1.05/share.

Financial news for CANF dated on 2018-12-10: Can-Fite Enters Into Collaboration Agreement to Explore Namodenoson's Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC

Financial news for CANF dated on 2018-11-30: Can-Fite Reports Results For 9 Months Ended Sep. 30, 2018: EPS \$(0.08) vs \$(0.14) In Same Period Last Year, Sales \$3.531M vs \$704K Year Over Year

Financial news for CANF dated on 2018-11-21: Can-Fite Shares Spike ~15% On Uptick In Volume; Not Yet Seeing Fundamental Reason To Justify Move Higher

Financial news for CANF dated on 2018-10-31: Can-Fite Biopharma Says Due To Patient Survival, Top Line Efficacy Results Of Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19

Financial news for CANF dated on 2018-08-31: 26 Stocks Moving In Friday's Pre-Market Session

Financial news for CANF dated on 2018-08-31: Can-Fite 1H'18 EPS \$(0.08) vs \$(0.10) In Same Period Last Year, Sales \$902K vs \$136K Year Over Year

Financial news for CANF dated on 2018-08-21: Can-Fite BioPharma Reports Enrollment Of First Patient In Comfort Phase III Trial Of Piclidenoson In Psoriasis

Financial news for CANF dated on 2018-08-06: Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Mon., Jul. 6, 2018

Financial news for CANF dated on 2018-08-06: Can-Fite Announces Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical; Can-Fite to \$2M Upfront; Up to \$74.5M in Milestones, Royalties

Financial news for CANF dated on 2018-07-17: Benzinga Pro's 5 Stocks To Watch Today

Financial news for CANF dated on 2018-07-17: Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug

Financial news for CANF dated on 2018-07-02: 38 Stocks Moving In Monday's Mid-Day Session

Financial news for CANF dated on 2018-07-02: Benzinga Pro's 5 Stocks To Watch Today

Financial news for CANF dated on 2018-07-02: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for CANF dated on 2018-07-02: Can-Fite BioPharma Shares are Trading Higher After Announces the Publication of a Paper Recommending Development of Anti-Liver Cancer Drugs Based on Namodenoson

Financial news for CANF dated on 2018-06-19: Can Fite Biofarma Shares Up 6.7% After Co. Gave Update On Phase II Trial Of Namodenoson For Advanced Liver Cancer; Co. Said Accumulated Safety Data Indicates 'Favorable' Drug Safety Profile

Financial news for CANF dated on 2018-06-19: Can-Fite BioPharma Offers Update On Status Of Phase II Advanced Liver Cancer Trial: Of 78 Patients Originally Enrolled, 19 Completed At Least 12 Cycles Of Treatment, 3 Completed At Least 24 Cycles

Financial news for CANF dated on 2018-06-19: Can-Fite Says Accumulated Safety Data Continues To Indicate A Favorable Drug Safety Profile

Financial news for CANF dated on 2018-06-15: Maxim Group Terminates Can-Fite

Biopharma Ltd Coverage

Financial news for CANF dated on 2018-06-13: 31 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CANF dated on 2018-06-13: Benzinga's Top Upgrades, Downgrades For June 13, 2018

Financial news for CANF dated on 2018-06-13: Benzinga Pro's 5 Stocks To Watch Today

Financial news for CANF dated on 2018-06-13: H.C. Wainwright Assumes Can-Fite Biopharma Ltd Sponsored ADR (Israel) at Buy, Announces Price Target \$8

Financial news for CANF dated on 2018-06-11: Benzinga Pro's 5 Stocks To Watch Today

Financial news for CANF dated on 2018-06-11: Can-Fite Reports On New Pre-Clinical Developments With Its NASH Drug Namodenoson; Co. Reports Robust Anti-NASH Effects When Drug Administered Orally, Says Data Supports Selection Of Primary Endpoint For Phase 2 Study

Financial news for CANF dated on 2018-06-04: 40 Biggest Movers From Friday

Financial news for CANF dated on 2018-06-01: 26 Stocks Moving In Friday's Mid-Day Session

Financial news for CANF dated on 2018-06-01: 26 Stocks Moving In Friday's Pre-Market Session

Financial news for CANF dated on 2018-06-01: Can-Fite Biopharma Ltd Sponsored ADR (Israel) Q1 EPS \$(0.05) Beats \$(0.06) Estimate, Sales \$632K Beat \$140K Estimate

Financial news for CANF dated on 2018-03-23: Can-Fite Reports FY17 Net Loss \$1.89M vs \$1.82M In FY16, Sales \$850K vs \$200K In FY16

Financial news for CANF dated on 2018-03-13: Sabby Management Reports 8.34% Stake In Can-Fite Biopharma

Financial news for CANF dated on 2018-03-09: Maxim Group Downgrades Can-Fite Biopharma Ltd Sponsored ADR (Israel) to Hold

Financial news for CANF dated on 2018-02-28: Can Fite Anticipates Phase II NASH Study Data Release To Occur In First Half Of 2019

Financial news for CANF dated on 2018-02-12: Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson

Financial news for CANF dated on 2018-02-05: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for CANF dated on 2018-01-31: Can-Fite Shares Down ~\$0.05-\$0.10 Over Last Min., Down 3.2% For Session As Traders Circulating Street Sweeper Alert From Monday; Watch For Rebound From Low

Financial news for CANF dated on 2018-01-29: StreetSweeper Issues Short Report On Can-Fite Biopharma

Financial news for CANF dated on 2018-01-25: Can-Fite Receives its First Payment of \$2.2M From Gebro For the Distribution of Piclidenoson, Up to \$7M of Additional Milestone Payments Eligible

Financial news for CANF dated on 2018-01-11: Can-Fite Says It Expects 2 Phase II Studies In Rheumatoid Arthritis And Psoriasis In 12 Months, Along With A Data Release From Phase II Liver Cancer Trial And A Complete Enrollment For The NASH Study

Financial news for CANF dated on 2018-01-08: Can-Fite BioPharma Reports Signing Of Up To \$9M Distribution Deal With Gebro Holdings For Piclidenoson In 3 European Countries

Financial news for CANF dated on 2018-01-03: Can-Fite Announces a Collaborative Research Agreement with Hadassah Medical Center, A Phase 2 Study of Namodenoson to Enroll NAFLD/NASH Patients

Financial news for CANF dated on 2017-12-19: 40 Biggest Movers From Yesterday

Financial news for CANF dated on 2017-12-18: 34 Stocks Moving In Monday's Mid-Day Session

Financial news for CANF dated on 2017-12-18: 31 Stocks Moving In Monday's Pre-Market Session

Financial news for CANF dated on 2017-12-18: Can-Fite Gives an Updated on its Phase 2 Liver Cancer Trial

Financial news for CANF dated on 2017-11-27: Can-Fite Reports Q3 EPS \$(0.12) vs \$(0.08) Est., Sales \$740K vs \$40K Est.

Financial news for CANF dated on 2017-11-27: Can-Fite Enrolls the First Patient in Phase II NAFLD/NASH Study with Namodenoson

Financial news for CANF dated on 2017-10-30: Can-Fite Reports Enrollment Of First Patient In ACROBAT Phase III Trial Of Piclidenoson In RA

Financial news for CANF dated on 2017-09-26: F-3 From Can-Fite BioPharma Shows Registration For \$50M Mixed Securities Shelf Offering

Financial news for CANF dated on 2017-09-01: Can-Fite 6 Month EPS \$(0.10), Sales \$152K vs \$60K Est.

Financial news for CANF dated on 2017-08-23: Can-Fite Receives \$500K Milestone Payment from Chong Kun Dang Pharma

Financial news for CANF dated on 2017-08-11: 18 Biggest Mid-Day Gainers For Friday

Financial news for CANF dated on 2017-08-11: Benzinga's Top Upgrades, Downgrades For August 11, 2017

Financial news for CANF dated on 2017-08-11: Maxim Group Initiates Coverage On Can-Fite Biopharma Ltd Sponsored ADR (Israel) with Buy Rating, Announces \$7.00 Price Target

Financial news for CANF dated on 2017-08-07: Can-Fite BioPharma Cleared to Initiate 2 Phase III Studies for Piclidenoson following Completion of Cardiodynamic Trial

Financial news for CANF dated on 2017-06-08: Can-Fite Concludes Successful Clinical Investigator Meeting for its ACROBAT Phase III Trial of Piclidenoson in the Treatment of RA

Financial news for CANF dated on 2017-05-30: Can-Fite BioPharma Files for 1.375M ADS Offering

Financial news for CANF dated on 2017-05-30: Monday's Market In 5 Minutes

Financial news for CANF dated on 2017-05-30: Can-Fite Q1 EPS \$0.04 vs \$(0.09) Est, Sales \$73K

Financial news for CANF dated on 2017-05-16: Can-Fite Files Clinical Trial Application with Health Canada for Piclidenoson

Financial news for CANF dated on 2017-04-26: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CANF dated on 2017-04-25: 20 Biggest Mid-Day Gainers For Tuesday

Financial news for CANF dated on 2017-04-25: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CANF dated on 2017-04-25: Can-Fite Reports Phase III ACROBAT Trial in RA Approved by Institutional Review Board

Financial news for CANF dated on 2017-03-31: Can-Fite Reports FY16 EPS \$(0.25) vs. \$(0.31) Est., Sales \$170K vs. \$370K

Financial news for CANF dated on 2017-02-28: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for CANF dated on 2017-02-28: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CANF dated on 2017-02-28: New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis

Financial news for CANF dated on 2017-01-19: 15 Biggest Mid-Day Losers For Thursday

Financial news for CANF dated on 2017-01-19: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for CANF dated on 2017-01-09: Can-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017

Financial news for CANF dated on 2016-12-21: Can-Fite Gets \$500K Milestone Payment

Financial news for CANF dated on 2016-12-16: 15 Stocks Moving In Friday's Pre-Market Session

Financial news for CANF dated on 2016-12-16: New Preclinical Data Show Can-Fite's Namodenoson Inhibits Liver Fibrosis

Financial news for CANF dated on 2016-11-25: The Market In 5 Minutes: Black Friday Closes Shortened Trading Week

Financial news for CANF dated on 2016-11-01: Can-Fite BioPharma Reached Agreement with EMA on Final Design of Global Pivotal Phase III Trial for Piclidenoson in Treatment of Psoriasis

Financial news for CANF dated on 2016-10-25: Can-Fite Signs Distribution Deal for Liver Cancer Drug CF102 in South Korea, Will Receive \$3M Upfront And Milestone Payments & Percentage Rate Of Royalties In Low Twenties

Financial news for CANF dated on 2016-10-19: Roth Capital Assumes Can-Fite Biopharma Ltd Sponsored ADR (Israel) at Buy

Financial news for CANF dated on 2016-10-13: Can-Fite Submits Protocol for Phase II Trial of CF102 in Treatment of NAFLD/NASH

Financial news for CANF dated on 2016-09-20: Can-Fite Shares Up 10% as Co. Earlier Offered Positive New Data on CF102's Live Protective, Regenerative Properties, Showed Candidate Protects Against Ischemia/Reperfusion Injury, Liver Hepatectomy

Financial news for CANF dated on 2016-08-29: Rodman & Renshaw Assumes Can Fite Biofarma at Buy, Announces \$6.00 PT

Financial news for CANF dated on 2016-08-26: Can-Fite Reports Six Months Ended Rev. \$111K, EPS \$0.10

Financial news for CANF dated on 2016-07-14: Can-Fite BioPharma Says Israel Court Approves Application to Extend Term of Series 11 Warrants until October 31, 2016

Financial news for CANF dated on 2016-07-05: Mid-Afternoon Market Update: Dow Falls 140 Points; Insys Therapeutics Shares Surge Following FDA Approval of Syndros

Financial news for CANF dated on 2016-07-05: 10 Biggest Mid-Day Losers For Tuesday

Financial news for CANF dated on 2016-07-05: Mid-Day Market Update: Crude Oil Down Over 4%; Himax Technologies Shares Spike Higher

Financial news for CANF dated on 2016-07-05: Mid-Morning Market Update: Markets Open Lower; Tesla's Deliveries Hit Near 2-Year Low

Financial news for CANF dated on 2016-07-05: Can-Fite BioPharma Reports Phase 2 Glaucoma Data Misses Primary Endpoint, No Statistically Significant Difference In CF101 Treated Group vs. Placebo; Sees No Immediate Path Forward In Galucoma

Financial news for CANF dated on 2016-06-27: Can-Fite BioPharma Announces Israel Court Grants Extension of Term of Series 11 Warrants Until July 14, 2016

Financial news for CANF dated on 2016-06-15: UPDATE: Can-Fite BioPharma Reports Psoriasis Drug Piclidenoson Inhibits 2 Inflammatory Cytokines IL-17 and IL-23

Financial news for CANF dated on 2016-06-15: Can-Fite BioPharma Reports New Data Demonstrating Psoriasis Drug Could Offer Efficacy Similar to Industry-Leading Biologics Without Harmful Side Effects

Financial news for CANF dated on 2016-06-14: Can-Fite Bio Pharma Files Application With Lod District Court in Israel to Approve Extension of Term of Series 11 Warrants until October 31, 2016

Financial news for CANF dated on 2016-06-07: Can-Fite Reports Submission of Psoriasis Phase III Protocol, Registration Plan to EMA for CF101

Financial news for CANF dated on 2016-06-01: Can-Fite Announces Agreement Reached with EMA on Phase 3 Trial Design

Financial news for CANF dated on 2016-06-01: Can-Fite Announces Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis

Financial news for CANF dated on 2016-05-27: Can-Fite Reports Q1 EPS \$(0.06), Sales \$57K

Financial news for CANF dated on 2016-04-13: Can-Fite BioPharma Announces Court

Approved Company's Application to Extend Term of Series 11 Warrants until June 30, 2016

Financial news for CANF dated on 2016-04-11: Can-Fite BioPharma Announces Positive Results for CF602, Plans to File Investigational New Drug Application

Financial news for CANF dated on 2016-04-01: Can-Fite Reports 2015 Financial Results, Provides Clinical Pipeline Update

Financial news for CANF dated on 2016-03-17: Can-Fite Gives Phase 3 Protocol Design, Registration TO EMA For CF101 In Treatment Of Rheumatoid Arthritis

Financial news for CANF dated on 2016-02-08: Napodano: CanFite Worth Multiples Of Current Valuation

Financial news for CANF dated on 2016-01-19: USPTO Issues Notice of Allowance for Can-Fite's Sexual Dysfunction Drug CF602

Financial news for CANF dated on 2016-01-11: Can-Fite Phase III Trials in RA, Psoriasis Expected to Commence in 2016; Planning Phase II Trial for New indication in NASH

Financial news for CANF dated on 2016-01-05: Can-Fite Submits Phase III Protocol to IRB for CF101 in the Treatment of Rheumatoid Arthritis

Financial news for CANF dated on 2015-12-07: Can-Fite Subsidiary Ophthalix, Announces Completion of Patient Enrollment in Phase II Glaucoma Study for CF101

Financial news for CANF dated on 2015-11-30: Can-Fite Biopharma +5% Premarket; H.C. Wainwright Raises PT from \$4 to \$6; Maintains Buy Rating

Financial news for CANF dated on 2015-11-27: Morning Market Gainers

Financial news for CANF dated on 2015-11-27: Can-Fite Sahres +17% Following Earnings Report

Financial news for CANF dated on 2015-11-27: Can-Fite Reports 9 Month Ended EPS (\$0.24)

Financial news for CANF dated on 2015-11-23: Morning Market Gainers

Financial news for CANF dated on 2015-11-23: Can-Fite Reports Supportive Pre-Clinical Data On CF102 For Treatment Of Non-Alcoholic Steatohepatitis

Financial news for CANF dated on 2015-10-28: Can-Fite Spikes to High

Financial news for CANF dated on 2015-10-22: Can-Fite +12.5% Premarket Following Announcement of New Study Demonstrating CF602 Mechanism of Action to Improve Sexual Dysfunction

Financial news for CANF dated on 2015-10-15: Can-Fite BioPharma 6K Out on Securities Purchase Agreement

Financial news for CANF dated on 2015-10-15: Can-Fite BioPharma Adjourns Today's Scheduled Annual Meeting till Wednesday, October 22, 2015 Due to Lack of Quorum

Financial news for CANF dated on 2015-10-13: Can-Fite Pharma REports \$4.8M Registered Direct Offering

Financial news for CANF dated on 2015-10-12: Morning Market Gainers

Financial news for CANF dated on 2015-10-12: Can-Fite BioPharma +9.5% Premarket on Announcement of EMA Orphan Designation for CF102

Financial news for CANF dated on 2015-10-12: EMA Grants Orphan Designation to Can-Fite's CF102 in the Treatment of Liver Cancer

Financial news for CANF dated on 2015-10-07: Can-Fite Biopharma Shares Spiking Higher

Financial news for CANF dated on 2015-10-07: Can-Fite to Deliver 2 Presentations on its Cancer Drug CF102 at the 20th World Congress on Advances in Oncology and 18th International Symposium on Molecular Medicine on October 8-10, 2015 in Athens

Financial news for CANF dated on 2015-10-01: Morning Market Losers

Financial news for CANF dated on 2015-09-26: Sabby Healthcare Master Fund, Ltd. Reports 9.57% Stake in Can-Fite BioPharma in 13G Filing

Financial news for CANF dated on 2015-09-25: Hearing Unconfirmed Market Chatter of

Baker Bros Stake in Canfite

Financial news for CANF dated on 2015-09-24: Morning Market Losers

Financial news for CANF dated on 2015-09-22: Morning Market Gainers

Financial news for CANF dated on 2015-09-21: Mid-Morning Market Update: Markets Open Higher; Lennar Tops Q3 Views

Financial news for CANF dated on 2015-09-21: Morning Market Losers

Financial news for CANF dated on 2015-09-21: Benzinga's Top #PreMarket Losers

Financial news for CANF dated on 2015-09-21: Can-Fite BioPharma Shares Fall 11% Premarket Following Announcement of \$9M Registered Direct Offering

Financial news for CANF dated on 2015-09-20: Can-Fite BioPharma Announces \$9M Registered Direct Offering; ~2.068M ADSs @\$4.35/ADS

Financial news for CANF dated on 2015-09-18: Can-Fite +108% @\$6.85

Financial news for CANF dated on 2015-09-18: Morning Market Gainers

Financial news for CANF dated on 2015-09-18: Can-Fite +19% Premarket

Financial news for CANF dated on 2015-09-17: Morning Market Gainers

Financial news for CANF dated on 2015-09-17: Benzinga's Top #PreMarket Gainers

Financial news for CANF dated on 2015-09-17: UPDATE: Can-Fite +56% at \$2.62

Financial news for CANF dated on 2015-09-17: Can-Fite +37% Premarket Following Announcement of FDA Fast Track Designation for CF102 in Treatment of Liver Cancer

Financial news for CANF dated on 2015-09-17: FDA Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer

Financial news for CANF dated on 2015-07-29: WHO Accepts 'Piclidenoson' as Proposed New Generic Name for Can-Fite's Lead Drug Candidate CF101

Financial news for CANF dated on 2015-07-23: Can-Fite Shares Move Higher; Mentioned as Play on Inotek

Financial news for CANF dated on 2015-07-23: Can-Fite Announces it Will Join Israeli Life Sciences Delegation to Japan on July 28 - 30, 2015

Financial news for CANF dated on 2015-06-29: US Stock Futures Signal Lower Start On Wall Street

Financial news for CANF dated on 2015-06-29: Can-Fite's CF602 Sexual Dysfunction Drug Backed by New Preclinical Data Progresses Towards an IND

Financial news for CANF dated on 2015-06-19: Can-Fite Subsidiary OphthaliX to Acquire Improved Vision Systems

Financial news for CANF dated on 2015-06-15: Can-Fite to Exhibit at Bio International Convention in Philadelphia on June 15 - 18, 2015

Financial news for CANF dated on 2015-06-10: Can-Fite Granted Notice of Allowance for Patent Covering Manufacturing Process of CF101 in the U.S.

Financial news for CANF dated on 2015-05-11: Can-Fite's Phase 2 Trial Approved In Europe

Financial news for CANF dated on 2015-05-11: Can-Fite Announces Phase II Liver Cancer Trial Approved in Europe

Financial news for CANF dated on 2015-05-04: Can-Fite subsidiary, OphthaliX, Signs Term Sheet to Acquire Improved Vision Systems Ltd.

Financial news for CANF dated on 2015-04-27: Morning Market Gainers

Financial news for CANF dated on 2015-04-27: Benzinga's Top #PreMarket Gainers

Financial news for CANF dated on 2015-04-27: UPDATE: Can-Fite Shares Rise 38% Premarket on Positive Results from Further Analysis of Phase II/III Psoriasis Trial

Financial news for CANF dated on 2015-04-20: Can-Fite Applies for Orphan Drug Designation in Europe for CF102 for Treatment of Liver Cancer

Financial news for CANF dated on 2015-03-30: Morning Market Losers

Financial news for CANF dated on 2015-03-30: Shares of Can-Fite Plummet from ~\$5.80 on Friday to \$2.80 in Pre-Market Action Following News Top-Line Results from Phase II/III Trial for CF101 Did Not Hit Primary Efficacy Endpoint

Financial news for CANF dated on 2015-03-23: US Stock Futures Edge Lower Ahead Of Existing-Home Sales Data

Financial news for CANF dated on 2015-03-23: UPDATE: Cipher Pharmaceuticals Acquires Canadian Rghts to CF101

Financial news for CANF dated on 2015-03-23: Can-Fite Signs Multi-Million Dollar Distribution Agreement for CF101 in Canada with Cipher Pharmaceuticals

Financial news for CANF dated on 2015-01-06: Can-Fite Reports Upcoming '15 Clinical Milestones for Drug Pipeline

Financial news for CANF dated on 2014-12-30: Can-Fite Completes Design of Rheumatoid Arthritis Phase III Study of CF101

Financial news for CANF dated on 2014-12-15: Can Fite Announces Approval from Regulatory Authorities in Bulgaria to Initiate Enrollment for Phase II Clinical Study in Glaucoma

Financial news for CANF dated on 2014-12-09: Can-Fite to Initiate Development Program of CF602

Financial news for CANF dated on 2014-12-02: UPDATE: Can-Fite Announces \$8M At-The-Market Registered Direct Offering

Financial news for CANF dated on 2014-12-02: Can-Fite BioPharma Announces \$8M At-The-Market Registered Direct Offering

Financial news for CANF dated on 2014-12-01: Morning Market Movers

Financial news for CANF dated on 2014-09-30: F-3 from Can-fite BioPharma Shows Registration for \$50M Mixed Securities Shelf Offering

Financial news for CANF dated on 2014-07-11: Morning Market Movers

Financial news for CANF dated on 2014-07-10: Morning Market Movers

Financial news for CANF dated on 2014-06-09: Can-Fite's Ophthalix Provides Update on Clinical Developments and Strategic Plans

Financial news for CANF dated on 2014-06-02: From Earlier: Can-Fite Says FDA has Agreed with its Phase II Liver Cancer Protocol

Financial news for CANF dated on 2014-04-29: Can-Fite Submits Protocol to U.S. FDA for Phase II Liver Cancer Study

Financial news for CANF dated on 2014-03-17: Can-Fite Phase II Study Protocol to Treat Patients with Advanced Liver Cancer with CF102 has been Approved by the IRB in Israel

Financial news for CANF dated on 2014-03-10: Can-Fite Completes \$5 M Private Placement

Financial news for CANF dated on 2014-03-10: Can Fite BioPharma Shares Halted News Pending

Financial news for CANF dated on 2013-12-30: Stocks Hitting 52-Week Lows

Financial news for CANF dated on 2013-12-30: Morning Market Losers

Financial news for CANF dated on 2013-12-30: Stocks To Watch For December 30, 2013

Financial news for CANF dated on 2013-12-30: Can-Fite Subsidiary Ophthalix Announces Phase III Study with CF101 for Dry Eye Syndrome did Not Meet Primary Efficacy Endpoint

Financial news for CANF dated on 2013-12-23: Morning Market Movers

Financial news for CANF dated on 2013-12-23: Can-Fite BioPharma Phase IIb Study with CF101 as a Monotherapy for Rheumatoid Arthritis Met Primary Endpoints

Financial news for CANF dated on 2013-12-05: Can-Fite Anticipates Results from

